Search

Ling Mei

from San Marino, CA
Age ~61
Get Report
Also known as:
Mei Ling
Related to:
Jihee Chang, 55Patty P Chan, 63Stephen Y Chan, 60Meimei M Lee, 72Mei M LeeTim Chan Yu, 85Henry H Lin, 70Mei Lingling
Connected to:
Andrew W Mei, 79Bing C Mei, 46Bruna E Mei, 31Danielle N Mei, 40Diana L Mei, 66Douglas Mei, 45Gwendolen Y Mei, 53Helena H Mei, 61Jianmin Mei, 58Jorge A Mei, 51

Ling Mei Phones & Addresses

  • San Marino, CA
  • 750 W Orange Grove Ave, Arcadia, CA 91006
  • San Gabriel, CA
  • Beverly Hills, CA

Business Records

Name / Title
Company / Classification
Phones & Addresses
Ling Mei
President
Hengshen International Inc
Business Services at Non-Commercial Site
2258 S Oak Knl Ave, Pasadena, CA 91108

Publications

Us Patents

The Role Of Il17Rd And The Il23-1L17 Pathway In Crohn's Disease

View page
US Patent:
20110177969, Jul 21, 2011
Filed:
Oct 1, 2009
Appl. No.:
13/121929
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Dermot P. McGovern - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
C40B 30/04
US Classification:
506 9, 435 611
Abstract:
The present invention relates to methods of diagnosing susceptibility to Crohn's Diseaese by determining the presence or absence of susceptibility variants at the IL17RD locus. in one embodiment, the present invention provides a method of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4, where the presence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4 is indicative of susceptibility to Crohn's Disease.

Methods Of Using Jak3 Genetic Variants To Diagnose And Predict Crohn's Disease

View page
US Patent:
20110189685, Aug 4, 2011
Filed:
Oct 22, 2009
Appl. No.:
13/124311
Inventors:
Kent D. Taylor - Ventura CA, US
Jerome I. Rotter - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Stephan R. Targan - Santa Monica CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
435 612
Abstract:
The present invention relates to methods of diagnosing and diagnosing susceptibility to Crohn's Disease by determining the presence or absence of risk variants at the JAK3 locus. In one embodiment, the present invention provides a method of diagnosing susceptibility to Crohn's Disease by determining the presence of a risk variant at the JAK3 locus, where the risk variant is associated with positive expression of ASCA and/or anti-I2.

Methods Of Using Genetic Variants To Diagnose And Predict Inflammatory Bowel Disease

View page
US Patent:
20100240043, Sep 23, 2010
Filed:
Oct 20, 2008
Appl. No.:
12/675718
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Dermot P. McGovern - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Xiaowen Su - Beverly Hills CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention relates to methods of diagnosing susceptibility to Inflammatory Bowel Disease and subtypes of Inflammatory Bowel Disease. In one embodiment, the present invention provides a method of diagnosing susceptibility to Inflammatory Bowel Disease by determining the presence of one or more risk variants at the DR3 locus, GATA3 locus, SIN(EFS) locus, BTLA locus, LIGHT locus and MAGE locus.

Diagnosis And Treatment Of Inflammatory Bowel Disease

View page
US Patent:
20220290235, Sep 15, 2022
Filed:
Jan 28, 2022
Appl. No.:
17/588089
Inventors:
- Los Angeles CA, US
Marla C. Dubinsky - Los Angeles CA, US
Carol J. Landers - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
International Classification:
C12Q 1/6883
G01N 33/68
Abstract:
This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.

Methods Of Diagnosis And Treatment Of Inflammatory Bowel Disease

View page
US Patent:
20180208988, Jul 26, 2018
Filed:
Mar 14, 2018
Appl. No.:
15/921160
Inventors:
- Los Angeles CA, US
Dermot P. McGovern - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
International Classification:
C12Q 1/6883
Abstract:
The present invention relates to methods of diagnosing and predicting susceptibility to Crohn's Diseaese and/or IBD, by determining the presence or absence of susceptibility to genetic variants, risk haplotypes and/or protective haplotypes. In an embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk variants at the IL12RB1, IL12RB2, IL17A, IL17RA, IL17RD and/or IL23R locus.

Methods Of Diagnosis And Treatment Of Inflammatory Bowel Disease

View page
US Patent:
20150337378, Nov 26, 2015
Filed:
May 26, 2015
Appl. No.:
14/722018
Inventors:
- Los Angeles CA, US
Dermot P. McGovern - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
Abstract:
The present invention relates to methods of diagnosing and predicting susceptibility to Crohn's Disease and/or IBD, by determining the presence or absence of susceptibility to genetic variants, risk haplotypes and/or protective haplotypes. In an embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk variants at the IL12RB1, IL12RB2, IL17A, IL17RA, IL17RD and/or IL23R locus.

Diagnosis And Treatment Of Inflammatory Bowel Disease

View page
US Patent:
20150259748, Sep 17, 2015
Filed:
May 29, 2015
Appl. No.:
14/726343
Inventors:
- Los Angeles CA, US
Marla C. Dubinsky - Los Angeles CA, US
Carol J. Landers - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
G01N 33/68
Abstract:
This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
Control profile
Ling Mei from San Marino, CA, age ~61 Get Report